2760250-80-2
2760250-80-2
Chemical Structure
Puxitatug samrotecan
Synonym(s): AZD 8205; P-Sam
- CAS No.: 2760250-80-2
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Puxitatug samrotecan]
Biological Activity: Puxitatug samrotecan (AZD 8205) is a B7-H4-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR+/HER2- breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Puxitatug samrotecan | 98.51% | Puxitatug samrotecan (AZD 8205) is a B7-H4-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR+/HER2- breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023;29(6):1086-1101. [Content Brief]
- [2]. Baird R D, et al. 300MO Puxitatug samrotecan (P-Sam, AZD8205) in patients (pts) with HR+/HER2–breast cancer (BC): A first-in-human phase I/IIa dose escalation and expansion study[J]. ESMO Open, 2025, 10.
Keywords
